Home
Product Pipeline
Manufacturing Platforms
Services & Support
About Us
Human Resources & Careers
Contact Us

Company Profile

Shanghai IxCell Biotech Co., Ltd. is a biopharmaceutical company specializing in the development and industrial production of cell-based drugs. With a focus on cellular therapeutics, we are dedicated to delivering high-quality, innovative products. Our core portfolio spans three key areas: mesenchymal stem cell drugs, induced pluripotent stem cell drugs, and immune cell drugs. These products are supported by a state-of-the-art cell manufacturing platform designed to meet the highest production standards.
Driven by independent research and a commitment to innovation, we have secured over 40 patents related to cell therapy and have set industry-leading standards in manufacturing. Our mesenchymal stem cell drug for the treatment of knee osteoarthritis is among the first in China to reach Phase III clinical trials, positioning it to become one of the country’s earliest commercialized stem cell therapies.
We operate a 4,000m² GMP-compliant production facility located in the heart of Zhangjiang Hi-Tech Park in Pudong, Shanghai. This facility integrates both research and manufacturing, enabling us to advance our mission of bringing cutting-edge cell therapies to market. The company has been recognized with several honors, including High-Tech Enterprise, Shanghai Specialized and New Small Enterprise, and Shanghai Key Enterprise status.

  • 00+Years

    Industry-Specific Experience

  • 0000㎡

    Cellular Manufacturing Facility

  • 00%

    Skilled Technical Staff

  • 00+ 

    Patent Portfolio

  • Corporate Mission

    Dedicated to advancing excellence in cell-based pharmaceuticals.

  • Corporate Vision

    To be a leading pioneer in the cellular drug manufacturing industry.

  • Core Values

    Integrity · Responsibility · Leadership

    Integrity :We believe in open, honest communication. Every member of our team is encouraged to speak with complete transparency, sharing their thoughts and insights fully and truthfully. Equally important is the role of the listener, who should engage with genuine attention and respect, fostering a culture of mutual trust and understanding.

    Responsibility :We are committed to facing challenges with integrity and courage. We do not tolerate deceit, avoidance, or the neglect of issues. Instead, we address problems head-on, resolve them with diligence, and embrace difficulties as opportunities for growth. Every individual takes full accountability for their actions, ensuring that responsibility is never shifted or deferred.

    Leadership :True leadership is built on initiative and the ability to lead by example. We value individuals who show competence and decisiveness in their work, and who are able to guide others with clarity and inspiration. As leaders, we aim to teach through both words and actions, creating a supportive environment where teams can thrive and succeed together.

Core Team

Our core team is composed of highly accomplished individuals from world-renowned institutions such as Harvard University and Yale University, as well as leading international companies in the cell pharmaceutical industry. They bring extensive expertise across the entire spectrum of cell therapy, including mesenchymal stem cells, induced pluripotent stem cells, and immune cells. Our team's comprehensive experience spans basic scientific research, process development, large-scale pharmaceutical manufacturing, and navigating the complexities of drug commercialization. This diverse and in-depth knowledge positions us to lead advancements in the field of cellular medicine.

With a steadfast commitment to excellence, we continuously strive to elevate the standards of cell-based pharmaceuticals, ensuring that every step forward is grounded in diligence and precision.

  • 2023

    ·Launched Phase I Clinical Trial for Mesenchymal Stem Cell Therapy for Stroke

    ·Completed Phase II Clinical Trial for Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

    ·Launched Phase III Clinical Trial for Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

    ·Advanced iPSC and Immune Cell Therapy Pipelines

    ·Recognized as a Specialized, Innovative Small and Medium-sized Enterprise in Shanghai

  • 2022

    ·Completed Clinical Phase II Enrollment for Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

    ·Received Clinical Trial Approvals from NMPA (National Medical Products Administration) for Stroke and Pulmonary Fibrosis Therapies

    ·Finalized Data Collection and Analysis for Phase II Knee Osteoarthritis Therapy

  • 2021

    ·Completed Phase I Clinical Project for Mesenchymal Stem Cell Drugs Targeting Knee Osteoarthritis

    ·Completed construction on 4000 m2 GMP laboratory located in the core area of Zhangjiang Hi-Tech Park in Pudong, Shanghai.

  • 2020

    ·Passed National High-Tech Enterprise Re-certification

  • 2019

    ·Received NMPA Approval for Mesenchymal Stem Cell Therapy for Knee Osteoarthritis Clinical Trial (National Medical Products Administration)

    ·Accredited as the "iPSC Clinical Transformation Technology Platform" by the Shanghai Science and Technology Commission

    ·Launched Phase I Clinical Trial for Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

  • 2018

    ·Submitted Investigational New Drug (IND) Application for Mesenchymal Stem Cell Therapy in Knee Osteoarthritis

  • 2017

    ·Contributed to the Revision of the "Technical Guidelines for Cell Therapy Products"

    ·Designated as a National High-tech Enterprise for the first time

  • 2016

    ·Developed First Cell Therapy Pipeline for Knee Osteoarthritis

  • 2015

    ·Incubated iPSC Technology, Secured Multiple National Grants

  • 2013

    ·Shanghai IxCell Biotech Co., Ltd. Established in Zhangjiang Hi-Tech Park, Shanghai

Qualifications and Honors

Shanghai Sci-Tech Innovation Enterprise Listing Training Database

Certified "Shanghai Induced Pluripotent Stem Cell Clinical Transformation Professional Technology Platform" by the Shanghai Science and Technology Commission

Joint Laboratory for Cell Quality Function Testing in collaboration with the Shanghai Institute of Biomedical Technology

Shanghai Specialized, Innovative, and Unique Small and Medium-sized Enterprise


National High-tech Enterprise

Production and Manufacturing Platform along with Product Pipeline

Manufacturing Platforms Clinical Development Pipelines